VERTEBRATE ANTIBODIES LIMITED

Their core work

Vertebrate Antibodies Limited is an Aberdeen-based biotech SME that produces custom antibodies derived from vertebrate animal hosts, supplying immunological reagents and antibody-based tools primarily to veterinary research and aquaculture diagnostics markets. Their core value to research consortia is providing specialist-grade antibodies — including those targeting fish parasites, livestock pathogens, and zoonotic agents — that are difficult to source from general suppliers. In H2020, they contributed this reagent expertise to large multi-partner projects tackling fish parasite control in European aquaculture (ParaFishControl) and veterinary biosafety infrastructure for high-containment animal infectiology (VetBioNet). They operate as a specialist service supplier rather than a research-performing organisation, making them a targeted addition to consortia that need validated immunological tools alongside academic partners.

What they specialise in

How they've shifted over time

Their first project (from 2015) centred on aquaculture: fish-specific immunology, parasite biology across protistans and metazoans, diagnostic kit development, and food safety — a tightly scoped aquaculture reagent role. By 2017 their second project pulled them toward broader veterinary biosafety: high-containment BSL3 infrastructure, zoonotic and epizoonotic preparedness, and farm animal infectiology — a step up in biosecurity relevance and scope. The shift suggests the company is leveraging its antibody production base to move beyond fish research into veterinary diagnostics for terrestrial livestock and zoonotic threat preparedness, two areas with stronger commercial pull.

They appear to be broadening from niche aquaculture antibody supply toward the more commercially attractive veterinary biosafety and emerging infectious disease diagnostics space, where demand from biosecurity-focused consortia and national veterinary labs is growing.

How they like to work

Vertebrate Antibodies has participated in two projects without ever coordinating, positioning themselves as a specialist supplier that large academic-led consortia bring in for specific reagent expertise. Both their projects involved very large networks (51 total unique partners across 17 countries), indicating they are comfortable operating as a small commercial node inside complex multi-institutional structures. This profile — small SME, specialist role, large consortia — means they likely contribute defined deliverables (antibody panels, diagnostic reagents) rather than leading work packages.

With 51 unique consortium partners across 17 countries from just two projects, Vertebrate Antibodies sits inside notably large European networks despite its SME size. Their geographic spread is pan-European, reaching well beyond the UK.

What sets them apart

Vertebrate Antibodies occupies a rare commercial niche: a private SME that produces custom antibodies specifically from vertebrate hosts for veterinary and aquaculture research applications — a reagent category that academic labs cannot easily produce internally and that large life-science suppliers rarely customise. Their direct experience in both BSL3-level veterinary biosafety projects and aquaculture parasite research makes them one of very few UK SMEs that bridge fish health diagnostics and farm animal zoonotic disease in a single portfolio. For consortium builders, they bring validated commercial reagent supply, regulatory-aware SME status, and a track record inside two of Europe's largest veterinary research networks.

Highlights from their portfolio

• ParaFishControl
  Their largest-funded project (EUR 75,000) and the clearest expression of their core antibody/diagnostic capability, spanning a five-year pan-European effort to develop parasite control tools across all major farmed fish species.
• VetBioNet
  A strategic step into high-biosafety veterinary infrastructure (BSL3), running to 2023 and placing them inside Europe's leading network of high-containment animal disease research facilities.